Friday, August 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

ClearPoint Neuro Reports Strong Quarterly Results and Plans for Revenue Growth in 2024

Elaine Mendonca by Elaine Mendonca
March 12, 2024
in Breaking News
0
Healthcare-IT-and-tech
0
SHARES
22
VIEWS
Share on FacebookShare on Twitter

ClearPoint Neuro (NASDAQ: CLPT) announced impressive quarterly results on March 12, 2024. The company reported a loss of $(0.19) per share, surpassing analyst expectations by 5 percent. Quarterly sales reached $6.810 million, exceeding estimates by 4.23 percent and showing a significant 31.62 percent increase from the same period last year.

In the fourth quarter of 2023, ClearPoint Neuro achieved record revenue of $6.8 million, marking a remarkable 32% growth from the previous year. The company also managed to reduce its cash burn and secure commitments for multiple new ClearPoint installations. Looking forward to 2024, ClearPoint Neuro plans to introduce new products and expand its services to drive revenue growth. The company is projecting revenue for the year to be between $28 million and $32 million.

CLPT Stock Shows Positive Price Momentum, Gains $0.55 in After-Hours Trading – March 12, 2024 Update

On March 12, 2024, CLPT stock showed signs of positive price momentum as it closed at $6.05, marking a $0.02 increase from the previous trading day. Additionally, in after-hours trading, the stock continued to climb, gaining an additional $0.55.

Investors should keep an eye on CLPT in the coming days to see if this positive momentum continues or if the stock encounters any obstacles that could cause it to retrace its gains.

CLPT Stock Performance Review: Mixed Results in Financial Metrics for March 12, 2024

On March 12, 2024, investors in CLPT stock saw mixed performances in terms of financial metrics. According to data from CNN Money, the company reported a total revenue of $20.55 million for the past year, representing a 26.09% increase compared to the previous year. However, the total revenue for the third quarter of the fiscal year was reported at $5.76 million, indicating a 3.16% decrease from the previous quarter.

In terms of net income, CLPT reported a net loss of $16.43 million for the past year, marking a 14.05% decrease compared to the previous year. On the other hand, the net loss for the third quarter was reported at $4.81 million, showing a 31.81% increase from the previous quarter.

Earnings per share (EPS) also showed mixed performances for CLPT stock. The company reported an EPS of -$0.68 for the past year, which was a 2.22% increase compared to the previous year. The EPS for the third quarter was reported at -$0.20, indicating a 31.96% increase from the previous quarter.

Overall, while CLPT stock saw some improvements in EPS and net income compared to the previous quarter, the decrease in total revenue for the third quarter may have raised some concerns among investors.

Tags: CLPT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Longboard Pharmaceuticals Reports Improved EPS for Fiscal Year 2023

what is a pre hire list

The Latham Group Forecasts Lower Revenue for Fiscal Year 2024

Hiring pre list

Title Latham Group Forecasts Lower Sales for First Quarter of 2024

Recommended

Palantir Stock

Palantir Shares Face Valuation Pressures Despite Strong Earnings

9 months ago
BridgeBio Pharma Stock

BridgeBio Pharma Investors Await Critical Heart Drug Data

9 months ago
Ocugen Stock

Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing

1 month ago
Airbnb Stock

Navigating Regulatory Headwinds and Innovation: Airbnb’s Strategic Crossroads

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

MSCI World ETF: Index Provider Rewrites the Rulebook for Fast-Moving Stocks

Airbus’ Paradox: A Slightly Smaller Forecast That Nobody Seems to Mind

Almonty Industries Rebounds From Index-Driven Exit as Tungsten Calculus Shifts Westward

OHB’s Two-Faced Half-Year: Record Orders Mask a Profit Squeeze That Spooked the Market

Trending

Nel ASA Stock
Analysis

Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding

by Jackson Burston
August 7, 2026
0

The Norwegian electrolyser maker Nel ASA is living a split-screen reality. Its order intake just exploded by...

SANDISK Stock

SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market

August 7, 2026
Bitcoin Stock

Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

August 7, 2026
Kioxia Stock

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

August 7, 2026
FALLBACK Stock

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

August 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding
  • SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market
  • Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com